The Use of Modified Templates in Early and Advanced Stage Nonseminomatous Germ Cell Tumor by Masterson, Timothy A. & Cary, Clint
Review Article
The Use of Modified Templates in Early and Advanced Stage
Nonseminomatous Germ Cell Tumor
Timothy A. Masterson and Clint Cary
Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Correspondence should be addressed to Timothy A. Masterson; tamaster@iupui.edu
Received 4 December 2017; Accepted 15 February 2018; Published 5 April 2018
Academic Editor: Jason M. Hafron
Copyright © 2018 Timothy A. Masterson and Clint Cary. +is is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in anymedium, provided the original work is
properly cited.
+e surgical management of both early and advanced stage germ cell tumors of the testis remains a complex process of surgical
decision making to maximize oncologic control while minimizing morbidity. Over the past 5 decades, the evolution of the surgical
template for retroperitoneal lymphadenectomy (RPLND) has resulted in important modifications to achieve these goals. In this
review, we will characterize the historical motivating factors that led to the modified template, outline patient and clinical factors in
selecting these approaches in both early and advanced stage disease, and briefly discuss future horizons for their implementation.
1. Introduction
Few topics generate more discussion and consideration than
the extent and laterality of the surgical template when
managing the retroperitoneum (RP) in germ cell tumor
(GCT) patients. +e implications of limiting the surgical
template inappropriately leave patients at risk for RP re-
lapses. Conversely, extending the template beyond necessary
boundaries increases the risk of surgical complications and
long-term side effects. Several modifications have been in-
corporated that allow for an optimization between func-
tional and oncologic outcomes. Understanding the historical
rationale for these alterations and the clinical scenarios in
which implementation of a limited dissection can be safely
integrated is imperative. For the purposes of this review, our
goal is to highlight the motivating factors and clinical ex-
perience that led to changes in the surgical boundaries for
retroperitoneal lymph node dissection (RPLND).
2. Historical Perspectives and Rationale for
Template Modifications
Prior to effective chemotherapy for metastatic GCT, wide
surgical resection of retroperitoneal (RP) disease was nec-
essary to provide patients their only chance for durable,
cancer-free survival. Additionally, cross-sectional imaging
was unavailable and staging of disease limited. Accordingly,
the burden of disease in this era was great; therefore, suprahilar
and bilateral retroperitoneal dissections were routinely per-
formed. With the development of curative, platinum-based
chemotherapy regimens [1] along with the introduction of
cross-sectional imaging of the abdomen with computed to-
mography [2] and discovery of serum tumor markers (STM)
[3], the management of testicular cancer patients shifted.
Surgery was associated with significantmorbidity, with the loss
of ejaculatory function representing themost pressing issue for
young men and their fertility, occurring in roughly 90% of
patients undergoing bilateral template dissections. Surveil-
lance protocols were implemented for patients without de-
tectable metastatic disease (CSI) to avoid this morbidity,
utilizing chemotherapy in those that relapsed or failed ob-
servation. Limitations of surveillance protocols included the
inaccuracies of clinical staging in roughly 30% of patients [4]
and the greater burden of surveillance imaging and salvage
treatments at the time of relapse.
Several surgical advancements improved our un-
derstanding of nodal dissemination of disease to the RP and
neural pathways that impacted ejaculatory function were
discovered, setting the stage for surgical modifications and
refinement. Preceded by cadaveric and lymphangiographic
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studies elucidating the primary and secondary lymphatic
drainage of the testicle [5–10], Ray et al. presented their
nearly 30-year experience with bilateral, infrahilar RPLND
in 283 patients [11]. Among the 122 patients with resectable
metastatic disease, they characterized distinct patterns of
spread based upon the laterality of the testicular primary.
+e authors noted the absence of crossover relative to the
primary landing zones among patients with solitary me-
tastases of the right or left testes. In 1982, Donohue et al.
reported their findings among 104 patients with node-
positive disease who were not previously treated with che-
motherapy and underwent routine full bilateral dissections,
including the suprahilar regions [12]. +is study confirmed
the predictable patterns of disease spread as reported by Ray
et al. and provided pathologic rationale for the safe omission
of suprahilar, interiliac, and contralateral RP dissections in
low-volume disease. +ese modifications resulted in a re-
duction in the risk of postoperative chylous ascites, re-
novascular injury, pancreatic complications, and improved
preservation of antegrade ejaculation.
Weissbach and Boedefeld reported on a prospective,
multi-institutional trial of 214 consecutive patients un-
dergoing a bilateral dissection for clinical stage II disease
[13]. +e goals of this study were to determine the local-
ization and distribution of solitary and multiple lymph node
metastases. +ese authors again confirmed the uncommon
occurrence of contralateral disease relative to the aorta in the
setting of early stage tumors, defined as solitary metastases
measuring 5 cm or less. More importantly, when a limited
template was compared prospectively by this same group
among patients with CSI disease, no differences were seen
regarding relapse rates or perioperative complications, while
preservation of ejaculatory function was noted in 74% un-
dergoing a modified dissection as compared to 34% subjected
to a radical (bilateral) dissection [14].
Despite data from several published series, incorporation
of these template modifications into clinical guidelines has
remained controversial. Patient selection remains key for
maximizing the cancer control and limiting the morbidity.
In the primary setting, the risk of contralateral spread in-
creases with increasing tumor burden. For patients with
residual disease after chemotherapy, locations of disease
both pre- and postchemotherapy, IGCCCG risk classifica-
tion, along with tumor size have been suggested as criteria to
consider when selecting patients for template modifications.
Included in Figure 1 are the current templates utilized at our
institution for right and left modified boundaries (A), in
addition to bilateral template surgery (B). +e following
sections report on the current data and guidelines.
3. Outcomes in Early Stage NSGCT
Several institutions have assessed oncologic and functional
outcomes with modifications in the surgical template over
time. While significant variability exists among groups as to
the type of modifications made to the template, outcomes
regarding RP relapse rate, and recovery of ejaculatory func-
tion are uniformly reported. In one of the earliest studies out
of Italy, Pizzocaro et al. reported on 61 CSI patients, of which
10 experienced relapse in the absence of adjuvant therapy.
None of these occurred in the RP and 87% reported pres-
ervation of antegrade ejaculation with template modification
alone [15]. Similar findings were seen in a cohort of 85 CSI
patients from Brigham &Women’s Hospital in Boston, again
with no RP recurrences identified and 94% recovering
antegrade ejaculation [16]. Donohue et al. from Indiana
published their experience with unilateral template mod-
ifications, this time with ipsilateral nerve-sparing [17]. In
this series of 75 patients published in 1990, 73 of which
were CSI and 2 patients had low-volume CSIIa disease.
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Figure 1: Template boundaries for left and right modified RPLND (a) and bilateral template rPLND (b).
2 Advances in Urology
One RP recurrence was reported and later salvaged. When
assessing survival outcomes across all studies, cancer specific
and overall survival approaches 100%.
Proponents of bilateral, infrahilar dissections with uni-
lateral or bilateral nerve-sparing have suggested that limited
templates subject patients to higher rates of unresected disease
in the RP, leaving them at greater risk for late relapse, higher
burdens of chemotherapy, and potentially a greater risk of
death. Eggener et al. reported upon 191 cases of pathologic
node-positive cases undergoing primary RPLND for early
stage NSGCT [18]. Comparing published templates to the
distribution of disease mapped within their cohort, they es-
timate that 3% to 23% of patients with unilaterally modified
dissections would have nodal disease outside of the field of
surgery. A couple points are worth further discussion in this
study. Interestingly, there were 136 patients with clinical stage
IIA disease; however, only 80 (58%) were found to have
pathologic disease. Further, there were 20 patients with ele-
vated tumor markers at the time of RPLND. In the only
prospective trial comparing outcomes between surgical ap-
proaches, no difference in oncologic outcomes was identified,
and a twofold increase in functional outcomes was reported
with the unilateral template (Weissbach). To date, no ran-
domized trials have compared template modifications to full
bilateral dissections for difference in cancer control, 90-day
morbidity, and long-term functional outcomes regarding
ejaculatory function. Additionally, the Eggener study omits
any consideration for intraoperative findings that may in-
fluence the judgment of the surgeon to expand the dissection.
Nevertheless, improving upon the oncologic and functional
outcomes reported among these open series when template
modifications are performed at high-volume centers with
therapeutic intent would be difficult to accomplish.
4. Postchemotherapy RPLND
Template Outcomes
Early experience in using full bilateral templates following
cisplatin-based chemotherapy was reported by Donohue
et al. in 1982 [19]. Given the uncertainties of frozen section
pathologic evaluation in the postchemotherapy setting and
bulky disease with what is now considered suboptimal
chemotherapy, the authors supported the use of complete
bilateral RPLND. Since that time, several centers have
investigated the oncologic safety of modified unilateral
templates in appropriately selected individuals in con-
temporary series. In 2007, Beck et al. evaluated 100 patients
who underwent a modified dissection with a median follow-
up of 31.9 months [20]. Patient selection criteria were:
nonseminomatous GCT’s with normal serum tumorsmarkers
after cisplatin-based chemotherapy and tumors limited to the
primary landing zone both before and after chemotherapy.
+ere were 4 recurrences during follow-up, all of which were
outside the boundaries of a full bilateral template. +is study
was recently updated with 10-year follow-up data with an
additional 3 patients demonstrating a recurrence [21]. Again,
no recurrences were within the bounds of a full bilateral
template with the majority of recurrences being in the chest.
An additional series of 102 patients from the Austrian group
also evaluated the safety of template surgery in the post-
chemotherapy setting [22]. +e inclusion criteria in this series
were normal serum tumor markers after first-line cisplatin-
based chemotherapy with stage II disease. All patients un-
derwent template surgery based on the location of the primary
tumor. +ere was 1 recurrence in the RP within the boundary
of a full bilateral template for a recurrence rate of 0.9% at
a median follow-up of 8.5 years. +e majority (73%) of these
patients demonstrated a complete response to chemotherapy
with residual masses <1 cm. Heidenreich et al. described the
German experience in 98 patients who underwent a modified
template RPLND [23].+e inclusion criteria in this series were
similar to the prior studies and also limited the residual mass
to ≤5 cm in diameter. One patient developed a RP recurrence
in this series for a 1% recurrence rate at 3 years of follow-up.
+ese studies in combination demonstrate a risk of RP re-
currence of 0.6% in approximately 300 patients.
Others have published on the pathologic findings of
disease outside the boundary of a modified template. For
example, Carver et al. published the results of 269 patients
who had a full bilateral template performed and described
the pathologic findings outside the bounds of a modified
template [24]. +ey demonstrate that extra-template disease
was present in 7% to 32% depending on the boundaries used
for template dissections. However, the inclusion criteria in
this study were quite different than other published reports.
In the Carver et al. study, unselected patients with bulky
disease, significant receipt of salvage chemotherapy regimens,
elevated STMs at the time of surgery, and positive pre-
operative imaging outside the modified template boundaries
were included. +ese factors limit the relevance of this study
in determining the utility of template surgery in the post-
chemotherapy setting.
5. Functional Outcomes with
Template Modifications
Historical comparisons for bilateral RPLND are associated
with loss of seminal emission and ejaculation in the majority
of patients. With the incorporation of unilateral templates,
preservation of antegrade ejaculation was attributable to the
exclusion of any dissection or disruption of the contralateral
efferent, postganglionic sympathetic nerve fibers as they
course to the hypogastric plexus. Donohue reported ejac-
ulatory rates of 90% with modified, unilateral templates
without any compromise in oncologic efficacy [4]. Similar
rates of preservation were reported from the Italian group
among 61 CSI patients [15]. In the only prospective trial
assessing functional and oncologic outcomes among pa-
tients undergoing either a unilateral template compared to
the standard bilateral template, the modified template was
associated with a twofold improvement in ejaculatory rates
without any greater risk of in field relapse [14]. With further
modifications to include ipsilateral nerve-sparing within the
surgical template, rates of ejaculatory preservation were
improved. Jewett et al. demonstrated feasibility in a series of
30 patients, with 18 of 20 patients in whom successful nerve-
sparing was accomplished ultimately recovering function [25].
+e Indiana group published their experience combining
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unilateral template modifications with ipsilateral nerve-
sparing in 1990. In this cohort of 75 early-staged patients,
100% were able to achieve successful antegrade ejaculation
[17]. In a more contemporary series of 135 men undergoing
nerve-sparing primary RPLND at Indiana, 134 achieve nor-
mal function, and nearly 75% were able to conceive [26].
While data exist describing the safety of template surgery
in the postchemotherapy setting from an oncologic stand-
point, functional data also support an improved ejaculatory
status in modified template surgery. In the Indiana series
with 10-year follow-up data, antegrade ejaculation occurred
in 97.7% of patients, who were contacted [21]. Additionally,
Heidenreich et al. evaluated the likelihood of being able to
perform nerve-sparing surgery and found that 74.5% versus
55.5% of patients could undergo preservation of the post-
ganglionic sympathetic nerve fibers in modified template
versus bilateral template surgery, respectively [23]. Fur-
thermore, antegrade ejaculation occurred in 85% of modified
template resections versus 25% of full bilateral resections in
their series, (p< 0.001). Additional clinical outcomes are also
improved with a modified template dissection in the ap-
propriately selected patient, such as shorter operative times,
less blood loss, less transfusions, and fewer postoperative
complications [23].
6. Future Directions
+emajority of the current data supports the oncologic safety
of modified template surgery in strictly defined cohorts. Ef-
forts to determine the safety in other patient populations such
as poor-risk disease and late relapse offer areas of potential
study. +ese studies would require meticulous design to
ensure patient safety. For example, patients with a late relapse
10 years following their primary tumor with a small solitary
recurrence in the ipsilateral landing zone could be reasonable
to apply modified template principles. +e assumption here
would be that the disease has declared itself to the ipsilateral
landing zone of the primary tumor and there has been
a 10-year lag time to monitor the contralateral side with no
recurrence.
Data surrounding the use of minimally invasive surgery
and template dissection is limited particularly in the post-
chemotherapy setting, but this should and will be held to the
same standards of the open approach. Oncologic outcomes
regarding the therapeutic value of template surgery in
laparoscopic and robot-assisted primary RPLND are sig-
nificantly lacking due to small numbers of patients, even
smaller numbers with true pathologic disease, and the
majority of patients with pathologic stage II disease receiving
adjuvant chemotherapy. While some early reports of nerve-
sparing success in the robotic settings are promising in the
primary RPLND setting [27], this is not consistent across
studies with some series demonstrating lower antegrade
ejaculation rates with the robotic approach [28, 29]. Others
have shown inferior ejaculatory rates in clinical stage I
patients with the laparoscopic technique compared to ro-
botic techniques [30]. Ejaculatory outcomes in the post-
chemotherapy setting with minimally invasive techniques are
unclear. Overall, the high bar of 99% ejaculatory success [26]
and subsequent fertility in open primary RPLND using
modified templates cannot be compromised by incorporating
a robotic approach.
7. Conclusions
With more than 35 years of experience, several studies have
confirmed the safety of modified templates for RPLND both
in the primary and postchemotherapy setting. Benefits in-
clude limiting the morbidity of surgery, without compro-
mising the therapeutic impact among appropriately selected
patients. Expansion of its use within other patient populations
warrants exploration but must be integrated in a thoughtful
manner to ensure patient outcomes are not compromised.
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